Inflammatory Mediators in Diabetic NeuropathyNatalie M. Wilson and Douglas E. Wright*
Department of Anatomy and Cell Biology, University of Kansas Medical Center, Kansas City, KS 66160, USA
- *Corresponding Author:
- Douglas Wright, PhD
Department of Anatomy and Cell Biology
University of Kansas Medical Center
Kansas City, KS 66160, USA
E-mail: [email protected]
Received date: November 11, 2011; Accepted date: December 17, 2011; Published date: December 22, 2011
Citation: Wilson NM, Wright DE (2011) Inflammatory Mediators in Diabetic Neuropathy. J Diabetes Metab S5:004. doi:10.4172/2155-6156.S5-004
Copyright: © 2011 Wilson NM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Diabetic neuropathy (DN) is the most common complication of diabetes mellitus, resulting in high health care costs and greatly affecting the quality of life of patients. The mechanism(s) responsible for the development of DN is currently unclear, but is likely multifactoral. While a great deal is still unknown about the mediators responsible for the development of DN, current knowledge of other neuropathic conditions suggest the involvement of a number of inflammatory mediators such as interleukins and chemokines. This review will outline the current literature of a number of inflammatory mediators in both human and rodent studies. As there is currently no therapeutic treatment for DN, this review will also provide an overview of therapeutics targeting inflammation and the ability of these therapies to improve the symptoms of DN.